Improving CAR T-Cell Therapies for Multiple Myeloma: Thomas G. Martin, MD

Video

The clinical professor of medicine, Helen Diller Family Comprehensive Cancer Center, UCSF, discussed CAR T-cell therapies and safety signals of cilta-cel.

Ciltacabtagene autoleucel (cilta-cel) has continued to produce deep and durable responses in heavily-pretreated patients with multiple myeloma, as seen in data from the phase 1/2 CARTITUDE-1 study (NCT03548207).1,2

Data from the CARTITUDE-1 study were presented at the 63rd Annual American Society of Hematology (ASH) Meeting, December 11-14, 2021,, by Thomas G. Martin, MD, clinical professor of medicine, Adult Leukemia and Bone Marrow Transplantation Program, and associate director, Myeloma Program, University of California San Francisco, and co-leader, Cancer Immunology & Immunotherapy Program, Helen Diller Family Comprehensive Cancer Center.

Further data on cilta-cel, as an earlier line of therapy in patients with only 1 to 3 prior lines of therapy, were also presented at ASH 2021. These data were from the CARTITUDE-2 study (NCT04133636), which found that progression-free survival (PFS) at 6 months was 90% (95% CI, 65.6–97.4).

CGTLive spoke with Martin to learn more about cilta-cel. He discussed safety signals seen in the CARTITUDE-1 study, including the development of secondary hematologic malignancies. He also discussed future research that needs to be done with cilta-cel, including targeting selections and determining its place in the treatment landscape of multiple myeloma.

REFERENCES
1. New data from CARTITUDE-1 Study show continued deep and durable responses of ciltacabtageneautoleucel (cilta-cel) in treatment of heavily pretreated patients with multiple myeloma. News release. Janssen. December 12, 2021. https://www.janssen.com/new-data-cartitude-1-study-show-continued-deep-and-durable-responses-ciltacabtagene-autoleucel-cilta
2. Martin T, Usmani SZ, Berdeja JG, et al. Updated results from CARTITUDE-1: Phase 1b/2 study of CiltacabtageneAutoleucel, a B-cell maturation antigen–Directed chimeric antigen receptor T cell therapy, in patients with relapsed/refractory multiple myeloma. Presented at: 63rd Annual ASH Meeting; December 11-14, 2021, Atlanta, GA. Abstract 549.
3. Cohen YC, Cohen DA, Delforge M, et al. Efficacy and safety of ciltacabtageneautoleucel (cilta-cel), a B-cell maturation antigen (BCMA)–directed chimeric antigen receptor (CAR) T-cell therapy, in lenalidomide-refractory patients with progressive multiple myeloma after 1–3 prior lines of therapy: Updated results from CARTITUDE-2. Presented at: 63rd Annual ASH Meeting; December 11-14, 2021, Atlanta, GA. Abstract 3866.
Recent Videos
David Barrett, JD, the chief executive officer of ASGCT
David-Alexandre C. Gros, MD, Eledon’s chief executive officer
David Barrett, JD, the chief executive officer of ASGCT
Alfred L. Garfall, MD, MS, associate professor of medicine (hematology-oncology) and director, Autologous Hematopoietic Cell Transplantation, Cell Therapy and Transplant Program, Hospital of the University of Pennsylvania; and section chief, Multiple Myeloma, Division of Hematology/Oncology, Department of Medicine, Perelman School of Medicine, University of Pennsylvania,
Reena Sharma, MD, an adult metabolic consultant at Salford Royal Hospital
Nirav Shah, MD, MSHP, associate professor of medicine, at the Medical College of Wisconsin
Bhagirathbhai R. Dholaria, MD, an associate professor of medicine in malignant hematology & stem cell transplantation at Vanderbilt University Medical Center
Reena Sharma, MD, an adult metabolic consultant at Salford Royal Hospital
Mark Hamilton, MD, PhD, a hematology-oncology and bone marrow transplant (BMT) cell therapy fellow at Stanford University
Barry J Byrne, MD, PhD, the chief medical advisor of MDA and a physician-scientist at the University of Florida
Related Content
© 2025 MJH Life Sciences

All rights reserved.